Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 2/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140110 | 0.94 | GPR35 (0.34) | GPR35KEAP1NFE2L2ALPLALPI | |
| SCHEMBL20080103 | 0.89 | MAPT (0.39) | GPR35KEAP1NFE2L2ALPLALPI | |
| SCHEMBL140403 | 0.89 | MAPT (0.39) | GPR35KEAP1NFE2L2ALPLALPI | |
| SCHEMBL12652596 | 0.88 | ALPL (0.35) | GPR35ALPLALPIMEN1KMT2A | |
| SCHEMBL12940662 | 0.85 | GPR35 (0.34) | GPR35ALPLALPIMEN1KMT2A | |
| SCHEMBL140675 | 0.85 | GPR35 (0.52) | GPR35MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL17861116 | 0.85 | GPR35 (0.52) | GPR35MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL12940612 | 0.83 | KDM4E (0.37) | GPR35MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL140404 | 0.83 | ALDH1A1 (0.39) | GPR35ALPLALPIMEN1KMT2A | |
| SCHEMBL16136587 | 0.80 | GPR35 (0.40) | GPR35KEAP1NFE2L2ALPLALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889849-B2 | Oxidized glutathione assay | PROMEGA CORPORATION (US) | 2021-01-12 | — | — | US | disclosed |
| US-20180030503-A1 | OXIDIZED GLUTATHIONE ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-02-01 | — | — | US | disclosed |
| US-20180030503-A1 | OXIDIZED GLUTATHIONE ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-02-01 | — | — | US | disclosed |
| US-9816127-B2 | Oxidized glutathione assay | PROMEGA CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-9816127-B2 | Oxidized glutathione assay | PROMEGA CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2611929-B1 | OXIDIZED GLUTATHIONE ASSAY | PROMEGA CORP (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2778234-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | Promega Corporation (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-1935986-B1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORP (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8476450-B2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120058501-A1 | OXIDIZED GLUTATHIONE ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-03-08 | — | — | US | disclosed |
| US-20120058501-A1 | OXIDIZED GLUTATHIONE ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-03-08 | — | — | US | disclosed |
| WO-2012030960-A1 | OXIDIZED GLUTATHIONE ASSAY | PROMEGA CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-7951550-B2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2272972-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | Promega Corporation (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20080299593-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1935986-A2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070015790-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299593-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | GLB1, NOD1, PYCARD | GPR35 3011/4885KEAP1 314/4885NFE2L2 1470/4885 |
| US-20070015790-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | GLB1, NOD1, PYCARD | GPR35 3523/4885KEAP1 1054/4885NFE2L2 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.